New vaccine combo aims to wipe out stubborn prostate cancer spots
NCT ID NCT07090148
Summary
This early-stage study is testing whether a new DNA vaccine, combined with an immunotherapy drug (nivolumab) and targeted radiation, can eliminate small areas of recurring prostate cancer that have spread. It's for men whose cancer has returned after prostate surgery but is limited to just a few spots. The main goal is to see if this combination can get rid of the cancer and is safe for patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Wisconsin - Madison
RECRUITINGMadison, Wisconsin, 53705, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.